Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd. to leverage mutual resource advantages and enhance its innovative drug pipeline [1][2] Group 1: Strategic Cooperation - The strategic cooperation agreement outlines the collaboration plan and rights of the parties involved [1] - Baiyang Pharmaceutical has the right to acquire the "JK1033 project rights" at a mutually agreed price once the project reaches a certain stage, which would expand its innovative drug pipeline [1] Group 2: JK1033 Project - The JK1033 project is an anti-fibrosis small molecule compound derived from traditional Chinese medicine, aimed at treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) [1] - The project has completed various studies, received clinical trial approval in China, and is set to start Phase I clinical trials in January 2025 [1] - JK1033 has a multi-target mechanism that can intervene in several key signaling pathways involved in pulmonary fibrosis, showing promising anti-fibrosis and anti-inflammatory effects [1] Group 3: Company Profiles - Jikun Pharmaceutical is an innovative drug development company with a focus on organ fibrosis, inflammation, and immune regulation, utilizing a dual-driven model of chemical and biological drugs [2] - Baiyang Pharmaceutical aims to optimize medical scenarios through technological innovation and has signed an agreement to acquire a 24% stake in Jikun Pharmaceutical, reinforcing its commitment to innovation and commercialization [2]
百洋医药(301015.SZ)：与济坤医药签署战略合作协议